Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

KNKarun NeupaneMoffitt Cancer CenterLPLauren C. PeresMoffitt Cancer CenterLLLeslie LauersdorfMoffitt Cancer Center

Discussion

Loading...

Member takes

Implication

Retrospective analysis shows elranatamab improves performance status in relapsed multiple myeloma, indicating efficacy in challenging cases.

Key Points

  • To evaluate the efficacy and safety of elranatamab in treating relapsed/refractory multiple myeloma in a real-world setting.
  • Conducted a retrospective analysis at a single cancer center.
  • Collected data on demographics, prior therapies, and performance status.
  • Assessed responses and adverse effects using standardized criteria.
  • Estimated survival outcomes with Kaplan-Meier and Cox regression analyses.
  • Overall response rate (ORR) was found to be 52%.
  • Median progression-free survival was 10.1 months.
  • High marrow burden of disease was associated with shorter progression-free survival and overall survival.

Cite This Study

Neupane et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d179https://doi.org/10.1182/blood-2025-5833
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium2026 · 7 citations
  2. 2Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study.2026 · 1 citations
  3. 3Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-32025 · 3 citations
  4. 4Comparison of elranatamab's progression-free survival, duration of response, and overall survival from MagnetisMM-3 versus real-world external control arms: A subgroup analysis of China-predominant treatment regimens2025
  5. 5Evaluation of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma and prior anti-CD38–directed therapy: MagnetisMM-32.2024 · 1 citations